The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pertuzumab (P) with trastuzumab (T) and chemotherapy (CTX) in patients (pts) with HER2-positive metastatic gastric or gastroesophageal junction (GEJ) cancer: An international phase III study (JACOB).
Josep Tabernero
Consultant or Advisory Role - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech/Roche; ImClone Systems; Lilly; Merck KGaA
Honoraria - Amgen; Merck KGaA; Novartis; Roche; Sanofi
Paulo Marcelo Hoff
Consultant or Advisory Role - GlaxoSmithKline (U); Roche (U)
Research Funding - AstraZeneca; GlaxoSmithKline; Roche
Lin Shen
Consultant or Advisory Role - Roche
Research Funding - Roche
Atsushi Ohtsu
Honoraria - Chugai Pharma; Taiho Pharmaceutical
Ron Yu
Employment or Leadership Position - Genentech/Roche
Stock Ownership - Roche
Jennifer Eng-Wong
Employment or Leadership Position - Genentech/Roche
Stock Ownership - Genentech/Roche
Yoon-Koo Kang
Consultant or Advisory Role - Novartis; Roche; Sanofi
Honoraria - Novartis; Roche; Sanofi
Research Funding - Novartis; Roche; Sanofi